Savara Inc(简称Savara)近日就其针对自身免疫性肺泡蛋白沉积症(Autoimmune PAP)的Molbreevi*研发项目,发布了最新的监管动态。
公司方面表示,相关进展将有助于推动该疗法的后续开发进程,为患者带来新的治疗希望。
Savara Inc(简称Savara)近日就其针对自身免疫性肺泡蛋白沉积症(Autoimmune PAP)的Molbreevi*研发项目,发布了最新的监管动态。
公司方面表示,相关进展将有助于推动该疗法的后续开发进程,为患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.